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Abstract
Background:  Feline leukemia virus (FeLV) induces degenerative, proliferative and malignant
hematologic disorders in its natural host, the domestic cat. FeLV-945 is a viral variant identified as
predominant in a cohort of naturally infected animals. FeLV-945 contains a unique sequence motif
in the long terminal repeat (LTR) comprised of a single copy of transcriptional enhancer followed
by a 21-bp sequence triplicated in tandem. The LTR is precisely conserved among independent
cases of multicentric lymphoma, myeloproliferative disease and anemia in animals from the cohort.
The 21-bp triplication was previously shown to act as a transcriptional enhancer preferentially in
hematopoietic cells and to confer a replicative advantage. The objective of the present study was
to examine the molecular mechanism by which the 21-bp triplication exerts its influence and the
selective advantage responsible for its precise conservation.
Results: Potential binding sites for the transcription factor, c-Myb, were identified across the
repeat junctions of the 21-bp triplication. Such sites would not occur in the absence of the repeat;
thus, a requirement for c-Myb binding to the repeat junctions of the triplication would exert a
selective pressure to conserve its sequence precisely. Electrophoretic mobility shift assays
demonstrated specific binding of c-Myb to the 21-bp triplication. Reporter gene assays showed that
the triplication-containing LTR is responsive to c-Myb, and that responsiveness requires the
presence of both c-Myb binding sites. Results further indicated that c-Myb in complex with the 21-
bp triplication recruits the transcriptional co-activator, CBP, a regulator of normal hematopoiesis.
FeLV-945 replication was shown to be positively regulated by CBP in a manner dependent on the
presence of the 21-bp triplication.
Conclusion: Binding sites for c-Myb across the repeat junctions of the 21-bp triplication may
account for its precise conservation in the FeLV-945 LTR. c-Myb binding and CBP recruitment to
the LTR positively regulated virus production, and thus may be responsible for the replicative
advantage conferred by the 21-bp triplication. Considering that CBP is present in hematopoietic
cells in limiting amounts, we hypothesize that FeLV-945 replication in bone marrow may influence
CBP availability and thereby alter the regulation of CBP-responsive genes, thus contributing to
altered hematopoiesis and consequent hematologic disease.
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Background
Feline leukemia virus (FeLV) is a simple gammaretrovirus
that induces degenerative, proliferative and malignant
hematologic disorders in its natural host, the domestic
cat. Like other natural retroviruses, FeLV is not a single
genomic species but is a genetically complex family of
closely related viruses subject to selective pressures in the
host. Variant genomes are generated during virus replica-
tion as a result of both error-prone reverse transcription
and recombination. The consequence of this variation is a
diverse population that is continuously shaped in vivo and
from which variants with selective advantages arise as pre-
dominant species. The variable clinical outcome of FeLV
infection is thought to reflect this genetic diversity [1,2].
FeLV-945, a natural FeLV variant, was originally identified
as the predominant species in a temporal and geographic
cohort of infected cats. FeLV-945 was originally derived
from a multicentric lymphoma of unknown phenotype
and subsequently identified in degenerative and prolifer-
ative diseases of myeloid and erythroid origin from the
cohort. FeLV-945 contains a unique sequence motif in the
long terminal repeat (LTR) comprised of a single copy of
transcriptional enhancer followed 25-bp downstream by
a 21-bp sequence triplicated in tandem. The sequence and
position of the 21-bp triplication in the FeLV-945 LTR was
observed to be precisely conserved among eight inde-
pendent multicentric lymphomas and in cases of myelo-
proliferative disease and anemia in animals from the
cohort [[3,4], Chandhasin et al., manuscript submitted].
The 21-bp triplication was previously shown to provide
transcriptional enhancer function to the LTR that contains
it, and to function preferentially in primitive hematopoi-
etic cells [5]. In K-562 cells, a human leukemia cell line
considered to be primitive and multipotential [6,7], the
FeLV-945 LTR was 12-fold more active than other natu-
rally occurring FeLV LTRs examined. Further, the FeLV-
945 LTR was preferentially active in K-562 cells, 4.2-fold
more active than in FEA feline embryo fibroblasts [5].
Interestingly, when the U3 region of the LTR containing
the 21-bp triplication was placed downstream of a heter-
ologous promoter, the preferential activity in K-562 cells
was lost. These findings suggest that the ability of the 21-
bp triplication to enhance transcription preferentially in
hematopoietic cells depends on the presence of the adja-
cent LTR binding sites in their natural array, a possibility
examined further in the present study. Previous studies
also showed that the 21-bp triplication in the FeLV-945
LTR confers a replicative advantage to the virus that con-
tains it, preferentially in hematopoietic cells [8]. This
growth advantage may account for the induction of
tumors of the type in which FeLV-945 was identified, and
may represent a selective advantage that contributes to
precise conservation of the unusual LTR sequence.
Regarding the molecular mechanism by which the 21-bp
triplication functions in the context of the LTR, at least
two possibilities have been considered. One possibility is
that the 21-bp triplication functions to maintain the
appropriate spacing in the LTR between the enhancer and
the promoter. A spacer function might be particularly rel-
evant in an LTR like FeLV-945 in which the enhancer is
not tandemly repeated. Substitution of the 21-bp repeat
element with unrelated sequence of the same length, how-
ever, was observed to ablate the replicative advantage,
thus indicating that the 21-bp triplication does not per-
form solely a spacer function [8]. An alternative mecha-
nism may be that the 21-bp triplication contributes
genuine enhancer function, perhaps via the binding of
nuclear transcription factors. Indeed, electrophoretic
mobility shift assay demonstrated that the 21-bp triplica-
tion contains binding sites for specific nuclear proteins.
These observations suggested that preserving the protein
binding sites may confer a selective advantage that
accounts for the precise sequence conservation of the 21-
bp triplication in this natural FeLV isolate [8]. The present
study examined this possibility further. Binding sites were
identified for the transcription factor, c-Myb, that crossed
the repeat junctions of the triplication. Further, once c-
Myb was bound to the triplication, the transcriptional co-
activator CBP was recruited and was shown to positively
regulate virus production. Considering that CBP is present
in hematopoietic cells in limiting amounts, these observa-
tions suggest that FeLV-945 replication in bone marrow
may influence CBP availability and thereby alter the regu-
lation of CBP-responsive genes, thus contributing to
altered hematopoiesis and consequent hematologic
disease.
Results
As described above, previous studies suggested that pre-
serving the protein binding sites may confer a selective
advantage that accounts for the precise sequence conser-
vation of the 21-bp triplication in the FeLV-945 LTR [8].
In the present study, the sequence of the 21-bp triplica-
tion was compared to a transcription factor binding site
database (TFSEARCH, based on TRANSFAC; [9]) in order
to identify potential binding proteins. This analysis iden-
tified two putative binding sites for the transcription fac-
tor c-Myb formed across the repeat junctions of the
triplication (Figure 1). The sequence of those sites, 5'-
AAACTG, closely matched the consensus c-Myb binding
sequence, YAACG/TG (Y = pyrimidine; [10,11]). Mis-
match between the putative binding site and the consen-
sus sequence was observed at position 1, a position whose
change from T to A is known to have little effect on bind-
ing affinity [12]. To determine whether c-Myb binds to the
FeLV-945 21-bp triplication, EMSA was performed by
reacting a radiolabeled triplication-containing probe with
nuclear extracts from K-562 cells in the presence ofVirology Journal 2004, 1:3 http://www.virologyj.com/content/1/1/3
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increasing amounts of a known high-affinity c-Myb bind-
ing site as competitor. K-562 cells were chosen because c-
Myb is known to be expressed and is thought to be a reg-
ulator of their differentiation along multiple hematopoi-
etic lineages [13]. The results demonstrated a significant
reduction in complex formation in the presence of the c-
Myb site competitor, especially at amounts in ≥ 100-fold
molar excess. In contrast, 250-fold molar excess of the
unrelated CREB binding site had no effect (Figure 2). To
confirm the presence of c-Myb in the specific protein-
DNA complex formed on the 21-bp triplication, super-
shift EMSA was performed using nuclear extracts from K-
562 cells in the presence of a monoclonal anti-c-Myb anti-
body. The results clearly showed decreased mobility of the
specific complex in the presence of the c-Myb antibody
(Figure 3A), but not in the presence of an isotype control
antibody (Figure 3B). As a control to confirm that c-Myb
binding required repetition of the 21-bp element, EMSA
was repeated with a homologous probe derived from
FeLV-A/61E, a natural isolate that contains only a single
copy of the 21-bp sequence in the LTR. The results dem-
onstrated no specific complex formation on the FeLV-A/
61E-derived probe (Figure 3C), confirming that the spe-
cific complex formed on the FeLV-945-derived probe is
attributable to the 21-bp triplication.
To evaluate whether c-Myb binding to the 21-bp triplica-
tion regulates LTR function, reporter plasmids were con-
structed in which expression of the firefly luciferase gene
was driven by the U3 region of an FeLV LTR containing
one, two or three copies of the 21-bp element. Reporter
gene constructs were introduced by lipid-mediated trans-
fection into feline embryonic fibroblasts (FEA) along with
increasing amounts of a c-Myb expression vector. Fibrob-
lasts were selected because the level of endogenous c-Myb
expression in those cells is low or absent [14,15]. The
results (Figure 4) demonstrated that the FeLV-945 LTR (3
× 21) responds to increasing levels of c-Myb expression to
an extent statistically indistinguishable from the positive
control, i.e., a reporter plasmid containing five tandem
Myb-responsive elements (5X MRE). In contrast, an FeLV
LTR containing only a single 21-bp element was
Diagram of the U3 region of the FeLV-945 LTR, indicating the transcriptional enhancer (hatched box), 21-bp triplication (open  boxes) and transcriptional promoter (Pro) Figure 1
Diagram of the U3 region of the FeLV-945 LTR, indicating the transcriptional enhancer (hatched box), 21-bp triplication (open 
boxes) and transcriptional promoter (Pro). Below the diagram is shown the sequence of the 21-bp triplication, indicating puta-
tive binding sites for the c-Myb transcription factor formed across the repeat junctions. The c-Myb binding site consensus 
occurs in the negative strand.
Electrophoretic mobility shift assays (EMSA) performed using  a radiolabeled probe representing the 21-bp triplication from  the FeLV-945 LTR Figure 2
Electrophoretic mobility shift assays (EMSA) performed using 
a radiolabeled probe representing the 21-bp triplication from 
the FeLV-945 LTR. Nuclear extracts (3.5 µg) from K-562 
cells were incubated with the radiolabeled probe (1 ng). 
Double-stranded competitor oligonucleotides were omitted 
from the reaction (lanes 0), or were included in increasing 
amounts from 10-fold to 250-fold molar excess (10-, 25-, 50-
, 100- and 250-fold excess shown). The competitors used 
contained a c-Myb consensus binding site (5'-TACAGGCAT-
AACGGTTCCGTAGTGA) or a CREB consensus binding 
site (5'-AGAGATTGCCTGACGTCAGAGAGCTAG). Also 
indicated is the migration of the radiolabeled probe without 
the addition of nuclear extract (lanes C).Virology Journal 2004, 1:3 http://www.virologyj.com/content/1/1/3
Page 4 of 10
(page number not for citation purposes)
unresponsive to c-Myb. The responsiveness of an LTR con-
taining two 21-bp elements was also examined, since the
21-bp duplication would be predicted to encode one c-
Myb binding site across the repeat junction. Interestingly,
this LTR responded to increasing c-Myb expression to a
low but statistically significant extent (p < 0.05 as com-
pared to 1 × 21; Figure 4). These data show that the tripli-
cation-containing LTR is responsive to c-Myb in a dose-
dependent manner and suggest that full responsiveness
requires the presence of both c-Myb binding sites. To con-
firm the latter finding, a point mutation previously shown
to ablate c-Myb binding [16] was introduced alternately
into each of the sites (Figure 5A). Synthetic oligonucle-
otides containing the respective mutations were substi-
tuted into the LTR, and luciferase reporter gene constructs
containing the mutant LTRs were introduced into FEA
cells along with increasing concentrations of a c-Myb
expression vector. LTRs in which either c-Myb binding site
was ablated were observed to respond only weakly to
increasing levels of c-Myb, and to significantly lower lev-
els than the wild type LTR containing both binding sites
(p < 0.05; Figure 5B).
Previous studies had shown that the 21-bp triplication
contributes enhancer function to the LTR in a cell type-
specific manner, and that it is significantly more active in
K-562 cells as compared to a fibroblast line [5]. In
Supershift EMSA in the presence of a c-Myb-specific antibody Figure 3
Supershift EMSA in the presence of a c-Myb-specific anti-
body. (A). Nuclear extracts (5 µg) from K-562 cells were 
incubated with the radiolabeled GS945 probe (2.4 ng) repre-
senting the 21-bp triplication from the FeLV-945 LTR. Shown 
are probe only (lane 1), complex formation in the presence 
of nuclear extract (lane 2), and complex formation in the 
presence of 200-fold molar excess of non-specific (lane 3) or 
specific competitor (lane 4). Reaction performed in the pres-
ence of monoclonal antibody to c-Myb (4 µg) resulted in 
supershift of the specific complex (lane 5) which was not 
observed in the presence of 200-fold molar excess of specific 
competitor (lane 6). (B). Lanes 1, 2 and 3 represent repeti-
tions of lanes 1, 2 and 5 of (A). Reaction with a isotype con-
trol antibody (lane 4) did not result in supershift. Indicated 
are the specific complex (solid arrow), non-specific com-
plexes (open arrows), and the supershifted complex (aster-
isk). (C). EMSA performed using the radiolabeled GS61E 
probe, which contains only a single copy of the 21-bp ele-
ment. Shown are probe only (lane 1), reaction performed in 
the presence of K-562 nuclear extract (5 µg; lane 2), and 
reaction performed in the presence of 100-fold molar excess 
of unlabeled GS945 (lane 3), GS61E (lane 4) or non-specific 
competitor (lane 5). The absence of complex formation using 
the GS61E probe demonstrates the requirement for the 21-
bp triplication.
Response to exogenous c-Myb expression of FeLV LTRs  containing variable numbers of the 21-bp element Figure 4
Response to exogenous c-Myb expression of FeLV LTRs 
containing variable numbers of the 21-bp element. Recom-
binant FeLV LTRs were constructed that contained 1, 2 or 3 
copies of the 21-bp element and were cloned into a firefly 
luciferase reporter plasmid. LTR reporter plasmids or a 5X 
MRE positive control plasmid (500 ng) were introduced by 
lipid-mediated transfection in triplicate into feline embryonic 
fibroblasts (FEA) together with the Renilla luciferase reporter 
plasmid pRL-SV40 (5 ng) and a c-Myb expression plasmid in 
increasing concentrations (0 – 500 ng). Cell lysates were har-
vested 24 hours later and luciferase activity was quantified. 
Data are reported as a ratio of firefly to Renilla luciferase 
activity. Shown are data from a representative experiment 
repeated three times independently.Virology Journal 2004, 1:3 http://www.virologyj.com/content/1/1/3
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hindsight, these results may be explained by the relatively
high levels of c-Myb expression in K-562 cells and its rel-
ative absence in fibroblasts [14,15]. When the U3 region
of the FeLV-945 LTR was placed downstream of a heterol-
ogous promoter, however, the cell type-specific preference
for enhancer function was lost [5]. One explanation for
these findings is that c-Myb bound to the 21-bp triplica-
tion may function through interactions with other pro-
teins bound to the LTR, and that such interactions require
the LTR binding sites to be present in their natural array.
Indeed, c-Myb is known to function in a combinatorial
manner with other transcription factors and co-activators
to activate target gene expression [14]. Studies were
performed in the present study to evaluate this possibility
further. First, an oligonucleotide containing only the 21-
bp triplication was cloned into a luciferase reporter plas-
mid upstream of a heterologous SV40 promoter. This con-
struct, when introduced into FEA cells, was observed to be
unresponsive to increasing levels of c-Myb expression
(data not shown). Thus, the presentation of c-Myb
binding sites through the 21-bp triplication is apparently
insufficient to regulate transcription in the absence of the
normally adjacent LTR enhancer and promoter. These
findings are consistent with the possibility that c-Myb
binding to the 21-bp triplication functions to activate
transcription by interacting with proteins bound to adja-
cent sites on the LTR. c-Myb is known to interact directly
with a number of different proteins, including the tran-
scriptional co-activator CREB-binding protein (CBP)
[14,15]. Indeed, CBP is thought to act as a bridge that
physically connects c-Myb to the promoter-bound basal
transcription machinery, thus stabilizing the transcrip-
tion-preinitiation complex [14,15,17]. Experiments were
therefore performed in the present study to examine the
possibility that c-Myb bound to the 21-bp triplication
interacts with CBP.
Response to exogenous c-Myb expression of FeLV LTRs  containing c-Myb binding site mutations Figure 5
Response to exogenous c-Myb expression of FeLV LTRs 
containing c-Myb binding site mutations. (A). Diagram of the 
21-bp triplication as contained in the FeLV-945 LTR, indicat-
ing the sequence of c-Myb binding sites across the repeat 
junctions of the triplication (+/+). LTRs were constructed in 
which the first (-/+) or second (+/-) binding site was mutated. 
(B). Firefly luciferase reporter gene plasmids containing the 
FeLV LTR with wild type or mutant c-Myb binding sites (500 
ng) were introduced by lipid-mediated transfection in tripli-
cate into feline embryonic fibroblasts (FEA) together with 
the Renilla luciferase reporter plasmid pRL-SV40 (5 ng) and a 
c-Myb expression plasmid in increasing concentrations (0 – 
500 ng). Cell lysates were harvested 24 hours later and luci-
ferase activity was quantified. Data are reported as a ratio of 
firefly to Renilla luciferase activity. Shown are data from a 
representative experiment repeated three times 
independently.
Supershift EMSA in the presence of antibody specific for c- Myb or CBP Figure 6
Supershift EMSA in the presence of antibody specific for c-
Myb or CBP. (A – C). Nuclear extracts (5 µg) from K-562, 
3201 or FEA cells were incubated with the radiolabeled 
GS945 probe (2.4 ng) representing the 21-bp triplication 
from the FeLV-945 LTR. Shown in each panel is specific com-
plex formation in the presence of nuclear extract (closed cir-
cle), and with the addition of monoclonal antibody to c-Myb 
or CBP (4 µg). Reduced mobility of the complex (supershift) 
is indicated (asterisk). (D) shows the same reactions per-
formed with nuclear extracts from FEA cells in which c-Myb 
was exogenously overexpressed.Virology Journal 2004, 1:3 http://www.virologyj.com/content/1/1/3
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Supershift EMSA was used to evaluate whether c-Myb and
CBP might be present in the specific complex that forms
on the 21-bp triplication. Specific complex formation was
observed using a radiolabeled probe representing the 21-
bp triplication in the presence of nuclear extracts from
either K-562 cells or feline 3201 T-cells. In both cases,
mobility of the complex was reduced (supershifted) when
reacted with antibody to c-Myb. When the same reaction
was performed in the presence of an antibody to CBP, an
identical supershift was observed (Figure 6A,6B). No com-
plex formation was observed when the probe was reacted
with nuclear extracts from FEA cells (Figure 6C), consist-
ent with the lack of c-Myb expression in fibroblasts
[14,15]. CBP is ubiquitously expressed [14]; therefore,
this observation indicates that CBP does not participate in
complex formation on the 21-bp triplication in the
absence of c-Myb. When c-Myb was expressed exoge-
nously in FEA cells, specific complex formation and super-
shift were observed in the presence of antibody to either
c-Myb or CBP (Figure 6D). Finally, analysis of FeLV-945
replication indicated a regulatory role for c-Myb binding
and recruitment of CBP to the 21-bp triplication. K-562
cells were infected with recombinant FeLV [8] containing
the LTR of either FeLV-945 or FeLV-A/61E, the latter
having only a single copy of the 21-bp element. A CBP
expression vector was introduced into cells chronically
infected with either virus, and virus production was meas-
ured three days later by quantifying reverse transcriptase
activity in the culture supernatants. The results showed
significantly increased levels of production of virus con-
taining the FeLV-945 LTR. In contrast, virus containing the
FeLV-A/61E LTR was unaffected (Figure 7). These findings
indicate that the 21-bp triplication in the LTR renders the
virus responsive to the amount of available CBP.
Discussion
The natural FeLV isolate, FeLV-945, was originally identi-
fied from lymphoid and other hematopoietic disorders in
a geographic and temporal cohort. A unique 21-bp repeat
motif in the FeLV-945 LTR was observed to be precisely
conserved among animals in the cohort that exhibited
malignant, proliferative or degenerative hematopoietic
diseases of non-T-cell origin [[3,4], Chandhasin et al.,
manuscript submitted]. The 21-bp triplication was shown
to enhance transcription from the FeLV LTR and to confer
a replicative advantage to the virus, at least in part through
the specific binding of unidentified nuclear proteins to
the repeat motif [5,8]. In the present study, sequence anal-
ysis revealed two potential c-Myb binding sites formed
across the repeat junctions of the 21-bp triplication (Fig-
ure 1). While the sequence of the potential binding sites
(AAACTG) did not match the consensus c-Myb binding
site precisely (YAACG/TG; Y = pyrimidine; [10,11]), the
sequence was observed to be as closely related to the con-
sensus binding site as are several sites in the HTLV-I LTR
that are known to bind c-Myb [18,19]. Indeed, electro-
phoretic mobility shift assays indicated the specific bind-
ing of c-Myb to the 21-bp triplication by showing that a
known high-affinity c-Myb binding site competed for
DNA-protein complex formation but an unrelated site did
not. It was noteworthy in these assays that significant
competition for complex formation occurred only when
the competitor was present at relatively high amounts (≥
100-fold molar excess; Figure 2). By comparison, c-Myb
binding to a consensus sequence in the bcl-2 promoter
was shown to be effectively competed by 50-fold molar
excess of a cold oligonucleotide carrying a high affinity c-
Myb binding site [20]. A possible explanation for this
difference may be that, while c-Myb can recognize a single
consensus binding site such as that found in the competi-
tor oligonucleotide we used, the natural recognition sites
are generally found in multiple, closely aligned copies as
in the 21-bp triplication. Thus, the affinity of binding to
the triplication may be higher than to the competitor. It is
further known that sequences flanking the consensus
binding site may also be important in determining c-Myb
binding affinity [21]. Electrophoretic mobility shift assays
performed in the presence of an antibody to c-Myb con-
firmed the presence of c-Myb in the specific DNA-protein
Regulation of FeLV replication in response to exogenous  overexpression of CBP Figure 7
Regulation of FeLV replication in response to exogenous 
overexpression of CBP. K-562 cells were chronically infected 
with recombinant FeLV containing the LTR of FeLV-945 or 
FeLV-A/61E. A CBP expression plasmid was then introduced 
by lipid-mediated transfection. Culture supernatants were 
collected 3 days later and reverse transcription activity was 
quantified as a measure of virus production. Results are 
reported as cpm/ml of 3H-TTP incorporated. The data 
shown were pooled from two independent experiments 
each performed in triplicate.
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complex (Figure 3A,3B), and confirmed that repeat of the
21-bp element was required for complex formation (Fig-
ure 3C).
The c-Myb transcription factor is a critical regulator of
gene expression, proliferation and differentiation in early
hematopoietic progenitors [14,15,22] and has been
exploited as a transcriptional regulator by many viruses
that infect bone marrow cells [19,23-25]]. Considering
that FeLV is known to replicate in the bone marrow
[26,27], and that FeLV-945 infection was associated with
various diseases of hematopoietic origin [Chandhasin et
al., manuscript submitted], it is likely that the tropism of
FeLV-945 in vivo included the hematopoietic progenitors
in which c-Myb is expressed. Considering this possibility,
we hypothesized that c-Myb may act as a transcriptional
regulator of FeLV-945. In support of this hypothesis,
reporter gene assays showed that an LTR containing the
triplication was responsive to c-Myb in a dose-dependent
manner (Figure 4), and that optimal responsiveness
required the presence of both c-Myb binding sites (Figure
5). The identification of c-Myb binding sites that spanned
the repeat junctions of the 21-bp triplication was
particularly noteworthy because such sites would not
occur in the absence of the repeat. Thus, a requirement for
c-Myb binding to the repeat junctions of the triplication
would exert a selective pressure to conserve its sequence
precisely. Results indicated further that when c-Myb binds
to the 21-bp triplication, it interacts with the transcrip-
tional co-activator CBP, a critical regulator of normal
hematopoiesis [17]. Identical electrophoretic mobility
supershifts were observed when protein-DNA complexes
were formed in the presence of antibody either to c-Myb
or CBP, consistent with the hypothesis that both proteins
are present in the same complex (Figure 6A,6B). The data
further indicated that c-Myb recruits CBP to the 21-bp
triplication, since no CBP-containing complex formation
could be demonstrated unless c-Myb was also expressed
(Figure 6C,6D). Finally, virus production was shown to be
positively regulated by CBP in a manner dependent on the
presence of the 21-bp triplication (Figure 7). These results
indicated that the interaction between c-Myb and CBP is
functional, and suggest that the c-Myb-mediated recruit-
ment of CBP to the FeLV-945 LTR could be responsible for
the previously reported replicative advantage conferred by
the 21-bp triplication [8].
CBP and c-Myb are thought to activate target genes in
hematopoietic progenitors through various mechanisms
of interaction. One of those mechanisms involves a bridg-
ing function in which CBP links c-Myb with components
of the basal transcription machinery, thereby establishing
and/or stabilizing the transcription complex [14,15,17].
While the mechanism of interaction was not investigated
in the present study, the bridging function is an intriguing
possibility because it might explain the observed require-
ment of the 21-bp triplication for an intact LTR enhancer
and promoter. Specifically, when the isolated 21-bp trip-
lication was positioned upstream of a heterologous pro-
moter, it did not confer responsiveness to exogenously
supplied c-Myb (data not shown). Previous studies had
similarly shown that the 21-bp triplication could not exert
its influence when placed downstream of a heterologous
promoter [5]. These observations indicated that transcrip-
tional activation of the FeLV-945 LTR through c-Myb/CBP
interaction requires that the LTR binding sites be present
in their natural array. The possibility that CBP exerts its
influence on the FeLV-945 LTR through a bridging func-
tion is significant because it implies that CBP acts
stoichiometrically. CBP is known to be present in bone
marrow cells in limiting amounts, playing a major role in
hematopoiesis through competitive utilization on target
promoters [17,28-31]]. Considering the competitive utili-
zation of limiting amounts of CBP in hematopoiesis, its
stoichiometric recruitment to the FeLV-945 LTR might
interfere with CBP availability and thereby alter the regu-
lation of CBP-responsive genes. Such alteration might
then contribute to altered hematopoiesis and consequent
hematologic disease.
Conclusions
FeLV-945 contains a unique 21-bp triplication in the LTR,
conserved among animals in a geographic cohort with
multicentric lymphoma, myeloproiferative disease or ane-
mia. Binding sites for the c-Myb transcription factor were
identified across the repeat junctions of the 21-bp triplica-
tion. Optimal responsiveness of the FeLV-945 LTR to c-
Myb was shown to require the presence of both c-Myb
binding sites. Since the binding sites would not occur in
the absence of the repeat, a requirement for c-Myb bind-
ing would be predicted to exert a selective pressure for
conserving the 21-bp triplication precisely. c-Myb binding
to the 21-bp triplication was shown to recruit CBP, a tran-
scriptional co-activator essential for hematopoiesis and
known to be present in limiting amounts. Interaction of c-
Myb and CBP with the 21-bp triplication was shown to
positively regulate virus production, and thus may be
responsible for the replicative advantage conferred by the
repeat sequence. Considering that CBP is present in
hematopoietic cells in limiting amounts, we hypothesize
that FeLV-945 replication in bone marrow may influence
CBP availability and thereby alter the regulation of CBP-
responsive genes, thus contributing to altered hematopoi-
esis and consequent hematologic disease.
Methods
Cell lines and viruses
K-562, a malignant multipotential human hematopoietic
cell line, was obtained from the American Type Culture
Collection (CCL-243) and was maintained in RPMI 1640Virology Journal 2004, 1:3 http://www.virologyj.com/content/1/1/3
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medium with 10% FBS. The FEA cell line, a continuous
line of feline embryonic fibroblasts, was obtained from
Dr. Jennifer Rojko and was grown in Eagle minimal essen-
tial culture medium supplemented with 10% fetal bovine
serum (FBS), 0.1 mM non essential amino acids and 50
µg/ml gentamicin reagent solution (Invitrogen, Carlsbad,
CA,). 3201 is an FeLV-negative thymic lymphoma cell line
of feline origin [32] and was maintained in 50% Leibovitz
L-15 medium/50% RPMI 1640 supplemented with 15%
FBS. Infectious recombinant FeLVs GA-945L and GA-61EL
were constructed from an infectious molecular clone of
FeLV-B/Gardner-Arnstein into which was substituted the
LTR of FeLV-945 or of FeLV-A/61E, respectively, between
EcoRV and Hinc II restriction enzyme sites [5,8]. The FeLV-
A/61E LTR was selected because it represents a naturally
occurring isolate of FeLV typical of those horizontally
transmitted among cats in nature, and it contains only a
single copy of the 21-bp element [33].
Electrophoretic mobility shift assays
A double-stranded oligonucleotide probe containing the
21-bp triplication and 40 bp of flanking sequence from
the FeLV-945 LTR was radiolabeled using the synthetic
oligonucleotide GS945 as template (5'-
GCTGAAACAGCAGAAGTTTCAAGGCCACTGCCAGCAG
TTTCAAGGCCACTGCCAGCAGTTTCAAGGCCACT-
GCCAGCAGTCTCCAGGCTCCCCAGTTGAC -3'), the fill-
ing primer (5'-CTGGTCAACTGGGGAGCCT-3') and the
Klenow fragment of DNA polymerase (Invitrogen,
Carlsbad, CA) to complete the duplex. A homologous
probe containing only a single copy of the 21-bp element
was similarly synthesized using the oligonucleotide
GS61E as template (5'-GCTGAAACAGCAGAAGTT-
TCAAGGCCACTGCCAGCAGTCTCCAGG CTC-
CCCAGTTGAC-3'). Nuclear extract from K-562 cells was
obtained from Active Motif (Carlsbad, CA). Nuclear
extracts from FEA and 3201 cells were prepared using the
Nuclear Extract Kit from Active Motif (Carlsbad, CA)
according to manufacturer specifications. Nuclear extracts
were also prepared from FEA cells following the lipid-
mediated transfection (Lipofectamine Plus reagent; Invit-
rogen, Carlsbad, CA) of FL-Myb, a c-Myb expression vec-
tor in which full length murine c-Myb cDNA was inserted
into the multiple cloning site of pcDNA3.1 (a gift of Dr.
Linda Wolff, National Cancer Institute). DNA-protein
binding reactions included 5 µg of nuclear extract and 2.4
ng of radiolabeled probe in a 20 µl reaction containing 1
mM Tris pH 7.5, 7.5 mM NaCl, 1 mM EDTA, 0.7% glyc-
erol, 0.1 mM DTT and 2 µg poly(dI-dC). Reactions con-
taining nuclear extracts from K-562 cells were incubated at
4°C for 30 minutes. Reactions containing nuclear extracts
from 3201 or FEA cells were incubated at 30°C for 30
minutes. In some reactions, unlabeled probe was added to
the reaction as a specific competitor, or HindIII/HaeIII-
digested bacteriophage lambda DNA was included as
non-specific competitor. Some reactions included as com-
petitor a double-stranded oligonucleotide containing a
known high-affinity c-Myb consensus binding site (5'-
TACAGGCATAACGGTTCCGTAGTGA) or a CREB consen-
sus binding site (5'-AGAGATTGCCTGACGTCAGA-
GAGCTAG). Protein-DNA complexes were resolved by
6% polyacrylamide gel electrophoresis in 0.25X TBE
buffer (1X TBE buffer is 89 mM Tris base, 89 mM Boric
acid and 2 mM EDTA). Gels were then dried at 80°C and
exposed to radiographic film for varying periods of time.
In some reactions, monoclonal antibody (4 µg) to either
c-Myb or CBP, or isotype control antibody, was added
after the 30-minute incubation period and incubated
overnight at 4°C. Complexes were then resolved by 6%
polyacrylamide gel electrophoresis as described above.
The mouse monoclonal IgG1 antibody to c-Myb was
raised against a recombinant protein corresponding to
amino acids 500–640 of the human protein (Santa Cruz
Biotechnology, Santa Cruz, CA). The mouse monoclonal
IgG1 antibody to CBP was raised against a peptide corre-
sponding to amino acids 2422–2441 of CBP of human
origin (Santa Cruz Biotechnology, Santa Cruz, CA).
Reporter gene constructs and luciferase expression assays
Luciferase reporter plasmids were constructed to contain
the U3 region of an FeLV LTR containing one, two or three
copies of the 21-bp element. The U3 region of the FeLV-A/
61E LTR, containing one copy of the 21-bp element, was
cloned into the firefly luciferase reporter plasmid pGL2-
Basic (Promega Corp., Madison, WI). The LTR was then
substituted between PstI and HincII restriction sites with
homologous sequences from a naturally occurring LTR
containing two 21-bp elements [Chandhasin et al., manu-
script submitted] or from FeLV-945, which contains three
21-bp elements. Luciferase reporter plasmids were also
constructed in which point mutations were introduced
into either the first or second c-Myb binding site in the 21-
bp triplication of the FeLV-945 LTR. Binding site mutants
were constructed by designing synthetic oligonucleotides
-/+  (5'-GCTGAAACAGCAGAAGTTTCAAGGCCACT-
GCCAGCAGATTCAAGGCCACTGCCAGCAGTTTCAAG-
GCCACTGCCAGCAGTCTCCAGGCTCCCCAGTTGAC-3')
and  +/-  (5'-GCTGAAACAGCAGAAGTTTCAAGGCCACT-
GCCAGCAGTTTCAAGGCCACTGCCAGCAGATTCAAG-
GCCACTGCCAGCAGTCTCCAGGCTCCCCAGTTGAC-3')
that contained a point mutation in the first or second
binding site, respectively (mutated base indicated by
boldface and underline). The indicated point mutation
had previously been shown to ablate c-Myb binding [16].
A double-stranded form of each sequence was generated
using the filling primer (5'-GAACTCTGGTCAACT-
GGGGAGCCTGGAGACTGCTG-3') and the Klenow frag-
ment of DNA polymerase. The resulting double stranded
oligonucleotides were digested with AluI/HincII and sub-
stituted into the LTR of FeLV-A/61E. The KpnI/PstI frag-Virology Journal 2004, 1:3 http://www.virologyj.com/content/1/1/3
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ment of the resulting recombinant LTR was then excised
and cloned into the pGL2-Basic luciferase reporter plas-
mid. Finally, a luciferase reporter plasmid was developed
that contained the isolated 21-bp triplication cloned
upstream of the SV40 promoter in pGL2-Promoter
(Promega Corp., Madison, WI). A double-stranded DNA
fragment containing the 21-bp triplication was generated
by PCR amplification using the oligonucleotide GS945
(described above) as template and primers fw945-kpn1
(5'- GCTCGGTACCAGCTGAAACAGCAGAAGTTTC) and
rv945-sac1 (5'- ATGCTGAGCTCAACTGGGGAGCCT-
GGAGACT). The resulting amplification product was
digested with KpnI/SstI  and inserted into the multiple
cloning site upstream of the SV40 promoter in the
reporter plasmid.
For reporter gene assays, 2 × 105 cells were seeded in trip-
licate into 6-well tissue culture plates. The next day,
reporter plasmids (500 ng) were introduced into cultured
cells by lipid-mediated transfection (Lipofectamine Plus;
Invitrogen, Carlsbad, CA) in the presence of pRL-TK (5
ng) in a 100:1 ratio. pRL-TK encodes Renilla luciferase and
was used as an internal control for transfection efficiency.
Firefly and Renilla luciferase activities were quantified 24
hours later using the Dual-Luciferase Reporter Assay Sys-
tem (Promega Corp., Madison, WI). Data from triplicate
wells were analyzed statistically using one-way ANOVA
and Bonferroni post test. Statistical significance was con-
sidered as p < 0.05. In some assays, the c-Myb expression
vector FL-Myb (described above) was added to the trans-
fection in increasing amounts (50 ng – 500 ng). The
5XMRE plasmid was used in reporter gene assays as a pos-
itive control. This plasmid contains five tandem c-Myb
binding sites cloned upstream of a luciferase gene (a gift
of Dr. Linda Wolff, National Cancer Institute).
Virus Replication Assay
5 × 105 K-562 cells, uninfected or chronically infected
with recombinant FeLVs GA-945L and GA-61EL
(described above) were seeded in triplicate into 24-well
tissue culture plates. A full-length CBP expression vector
(4 µg; a gift from Dr. Matthew Burow, Tulane University
Medical School) was introduced into the cells by lipid
mediated transfection using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA). Culture supernatants were
collected three days later and reverse transcriptase activity
was quantified as previously described [8]. Data from trip-
licate wells were analyzed statistically using one-way
ANOVA and Bonferroni post test. Statistical significance
was considered as p < 0.05.
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